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Impact of changes in perinatal care on bronchopulmonary dysplasia: an 
overview of the last two decades 
Abstract 
Objective: To compare the clinical approach and outcomes of bronchopulmonary 
dysplasia (BPD) patients in the last two decades (1996-2005 vs 2006-2015) in our 
neonatal intensive care unit.  
Methods: Out of 1196 admissions, 96 had BPD and were dichotomized into two 
groups according to the year of birth (1996-2005 and 2006-2015). Their clinical data were 
studied and conclusions were drawn about their morbimortality. 
Results: From 1996-2005, although infants were more severely ill (more small for 
dates, more lower Apgar Scores), there was a decrease in mortality (14.4vs.23.3%, 
P<0.001) and in BPD prevalence (6.1vs9.7%, P=0.023). In delivery room, early nasal 
continuous positive airways pressure was used in 42.1vs1.6%, P<0.001 and tracheal 
intubation, in 70.6vs96.8%, P<0.001. We observed an increase on the median duration of 
non-invasive ventilation (45.5 vs 22.5 days, P<0.001) and decrease of invasive ventilation 
(20 vs 39.5 days, P=0.013) from 1996-2005. On this, patients had more retinopathy (44.1 
vs 22.6%, P=0.028) and intraventricular hemorrhage (38.2 vs 12.9%, P= 0.004), probably 
related to a more severe status at birth. 
Conclusions: Improvement on perinatal and neonatal intensive care practices, 
namely the use of non-invasive methods of mechanical ventilation, implemented on the 
last years contributed to the better evolution of our preterm infants. 
 
Keywords: Bronchopulmonary dysplasia, preterm, newborns, neonatal intensive care, 
respiratory outcome 
 
Introduction 
 Bronchopulmonary dysplasia (BPD) is a frequent complication in preterm infants 
and its multifactorial etiology has not been fully established yet [1,2]. Multiple risk factors 
for BPD are known, namely, mechanical ventilation, inflammation and infection [3]. 
Prematurity is the most important risk factor and the incidence of BPD is inversely 
proportional to gestational age and birth weight [4].   
The definition of BPD has undergone changes over time. Initially, BPD was 
described as a consequence of positive-pressure ventilation and oxygen therapy which 
cause severe lung injury proven by histologic evidences (inflammation, protein-rich 
edema, airway epithelial metaplasia, peribronchial fibrosis and hypertrophy of respiratory 
tract vascular smooth muscle), « the classic BPD» [5,6].  
However, as time went by, perinatal care has improved and now very immature 
preterm infants have more chances to survive with BPD. These extremely low gestational 
age newborns frequently are born in the course of the late canalicular or early saccular 
stages of lung development and it seems to disturb the normal development of alveoli and 
vessels, resulting on the called « the new BPD»[7].  
Initially, infants with BPD were mainly treated with invasive mechanical 
ventilation (IMV) and drugs such as diuretics and postnatal steroids. Nowadays, although 
there is no effective treatment for BPD, preventive strategies are of great importance 
[8,9]. 
  The aim of this study was to describe and compare the clinical approach and the 
outcomes of patients with BPD in last two decades in our NICU. 
 
 
 
Material and Methods 
Infants with birth weight less than or equal to 1500g or less than or equal to 32 
weeks gestational age admitted to our center (a level III neonatal intensive care unit) 
between 1st january 1996 and 31th december 2015 were included in this retrospective 
study.  
Outborn neonates, children with major malformations, chromossomopathies 
and/or TORCH infections (Toxoplasmosis, Other (syphilis, varicella-zoster, parvovirus 
B19), Rubella, Cytomegalovirus and Herpes infections) were excluded.  
Characteristics as gender, gestational age, birth weight, antenatal steroid pulses, 
mode of delivery, respiratory support in the delivery room and in the NICU, Apgar score, 
presence of respiratory distress syndrome (RDS), the need for exogenous surfactant, the 
need for oxygen therapy, the prevalence of BPD and major morbidity conditions 
(pneumonia, pneumothorax, sepsis, meningitis, patent ductus arteriosus, necrotizing 
enterocolitis, severe intraventricular hemorrhage, retinopathy of prematurity, cystic 
periventricular leukomalacia), length of mechanical ventilation and oxygen therapy, 
length of parenteral nutrition, length of NICU stay and survival were collected from 
clinical charts.  
 The diagnosis and classification of BPD was made according to the National 
Institute of Health Consensus Definition of Bronchopulmonary Dysplasia [10]. 
Gestational age (completed weeks) was assessed by menstrual age (women with 
regular menstrual cycles), ultrasound examination (when a discrepancy of two or more 
weeks existed between the gestational age calculated by menstrual dating and the age 
derived sonographically or in the absence of a menstrual date) [11] or the New Ballard 
Score (in the absence of obstetrical indexes) [12].  
Small for gestational age was defined as a birth weight below 10th centile of 
Fenton’s fetal growth charts [13].   
Early nCPAP was considered if started in the first 15 minutes after birth and its 
failure was considered if patients needed invasive ventilation in the first 72 hours of life. 
The 5th minute Apgar scores were registered and dichotomized in two groups (<7 
and ≥7).  
RDS diagnosis was made on a combination of clinical and radiographic features 
according to the criteria of RDS of the Vermont Oxford Network: PaO2<50mmHg in 
room air, a requirement for supplemental oxygen to maintain PaO2>50mmHg or to 
maintain a pulse oximeter saturation over 85% within the first 24 hours of life and a chest 
radiograph with reticulogranular appearance to lung fields with or without low lung 
volumes and air bronchograms within the first 24 hours of life. 
 
Histological chorioamnionitis was defined according to Blanc’s classification [14] 
and all the stages of chorioamnionitis were analyzed together.  
Proven neonatal sepsis was defined as any systemic bacterial or fungal infection 
documented by a positive blood culture.  
In all cases of preterm delivery whenever an infection cause cannot be excluded, 
a combination of ampicillin and gentamicin is used as first line therapy, while waiting for 
the results of blood culture.   
For the diagnosis and staging of necrotizing enterocolitis (NEC) we used the 
criteria of Bell [15]. 
Retinopathy of prematurity (ROP) was staged according to the international 
classification [16,17]. 
            Intraventricular hemorrhage (IVH) was classified according to Papile at al [18]. 
Periventricular leukomalacia (PVL) was classified according to L. de Vries and 
Rennie [19]. 
Hemodynamically significant patent ductus arteriosus (PDA) was diagnosed 
considering echocardiographic findings. The first evaluation was usually done between 
24 and 72 hours of life with daily evaluations until closure of the ductus. The standard 
treatment was indomethacin until 2010, and ibuprofen after this date.  
  At our center, until 2003, the antenatal steroid regimen included dexamethasone 
(24 mg divided into two intramuscular doses every 12 h). Since then, treatment has 
consisted of betamethasone (24 mg divided into two intramuscular doses 24 h apart) in 
pregnancies at risk of preterm labor between 24 and 35 weeks gestation. 
 Caffeine was routinely used in all preterm infants since the first day of life until 
34 weeks of corrected age [20]. 
Oxygen was used to maintain saturations given by pulse oximetry in the range of 
88%-94% for RDS and ≥95% for established BPD until 2007. After this year, in preterm 
babies with RDS receiving oxygen, the saturation target is 90%-95% [20]. 
Spontaneous breathing infants were stabilized with continuous positive airways 
pressure (CPAP) of at least 5-6 cmH2O via mask or nasal prongs. Intubation was used in 
infants who did not respond to CPAP and in these babies surfactant was administrated 
[20]. For non-invasive mechanical ventilation we used Infant Flow® SiPAP System (Care 
Fusion, Yorba Linda, California, U.S.A.). 
Exogenous surfactant was administered for RDS by endotracheal tube in neonates 
on invasive mechanical ventilation or by INSURE (intubate-surfactant-extubate) in 
preterm infants requiring FiO2>0.40 and/or arterial PCO2>65mmHg and pH<7.20. 
The DART protocol was used if mechanical ventilation and oxygen therapy are 
increasingly needed after 10 days of life and the baby could not be weaned off invasive 
ventilation [21].  
In 2003 we started to use volume guarantee with synchronized ventilator modes 
(pressure support ventilation, synchronized intermittent mandatory ventilation or 
synchronized intermittent positive pressure ventilation), using Babylog 8000 Plus®, 
Dräger, Lubeck, Germany and Fabian HFO® , Acutronic Medical Systems, Hirzel, 
Switzerland.    
Parenteral nutrition was started in the first day of life and enteral nutrition, as soon 
as possible, according the clinical stability of the patient. According to our protocol 
parenteral nutrition starts with 70-80 ml/kg/d on the first day of life with daily increments 
of 10-15 ml/kg/day to a maximum of 150 ml/kg/day in the 1st week of  life [22]. 
Statistical analysis  
 The statistical analysis was performed using SPSS® for Windows, version 23. 
Continuous variables were characterized by mean (± standard deviation) or median 
(minimum-maximum) if there was symmetric or asymmetric distribution, respectively, 
and categorical variables by absolute and relative frequencies. To compare continuous 
variables, parametric tests (independent t test) or non-parametric tests (Mann Whitney-U 
test) were used, and Chi-Square or Fisher’s exact test to compare categorical variables, 
the latter for expected values below 5. A multivariate analysis by logistic regression was 
performed to evaluate the evolution of morbidity in newborn with BPD between both 
epochs.  A P value below 0.05 was considered statistically significant. 
 
The study protocol was approved by the Ethics Committee of our hospital. 
 
Results 
Out of 1196 neonates ≤ 1500g of birth weight or ≤ 32 weeks gestational age, 229 
(19.1%) died, being 149 (23.3%) in the first decade and 80 (14.4%) in the second one, 
(P<0.001) and 96 (8.0%) had BPD as discharge diagnosis (table1).  
Maternal, prenatal and perinatal data are shown in table 2. 
With regard to neonatal period, there was a significant decrease on invasive mechanical 
ventilation median duration (39.50 days from 1996 to 2005 and 20.00 from 2006 to 2015) 
and a significant increase on nCPAP median duration (22.50 days from 1996 to 2005 and 
45.50 days from 2006 to 2015). ROP and IVH had a significantly increase in the second 
decade (22.6% vs. 44.1% and 12.9% vs. 38.2%, respectively).  
There was a significant lower incidence of nosocomial sepsis among preterm 
infants admitted in our NICU (83.9% from 1995 to 2005 and 64.7% from 2006-2015) in 
the second decade, as shown in table3. 
A multivariate analysis by logistic regression revealed in the second epoch an 
OR= 8.112 (95%CI: 1.396-47.134; P= 0.020) for ROP and OR = 12.313 (95%CI: 1.921-
78.920; P= 0.008) for IVH.  
 
Discussion 
In the last decades, there have been several changes in perinatal care around the 
world with a consequent implementation of the clinical better practices during pregnancy 
as well as in management of the preterm infants.  Our hospital accompanied these changes 
having as main objective the improvement of patient’s outcome, favoring them the better 
quality of life.  Our data showed an improvement in morbimortality of preterm infants 
admitted in our NICU in last two decades, as shown in table 1. 
There has been a statistically significant increase in pregnancy associated 
pathologies as preeclampsia and flows changes, which may be related to the birth of more 
small for gestational age infants and consequently with more severe neonatal 
consequences. However, some studies showed that hypertensive disease during 
pregnancy is a protective factor for major IVH [23,24]. Our results did not show a 
decrease in IVH despite the increase of hypertensive disease on pregnancy and it can be 
related with a small sample or with better diagnostic acuity for IVH.  
In the twentieth century, the National Institutes of Health and the American 
College of Obstetricians and Gynecologists published a consensus statement defending 
the use of antenatal steroids in preterm deliveries of 24 to 34 of weeks gestational age in 
order to induce fetal maturation and reduce the risks for RDS, IVH and neonatal death 
[25]. According to our results the number of completed antenatal steroids cycles increased 
since 2006, showing better obstetric practices. 
In addition to the admission of more small for gestational age infants, the worse 
5th Apgar scores on the second decade also indicate that, from 2006 onwards, there has 
been an admission of more severe patients, and consequently, a greater number of 
neonatal consequences such as ROP and IVH. The significant increase on ROP incidence 
in the second decade may be due to the admission of more severe patients, but it can be 
also due to the improvement in diagnostic acuity, as previous mentioned for IVH. 
Despite the clear admission of more severe patients in the second decade, it was 
found a statically significant decrease in invasive mechanical ventilation (and in its 
duration) and increase in the use and duration of non-invasive mechanical ventilation 
(nCPAP). Also, on the delivery room, there was a higher prevalence of the use of early 
nCPAP. This highlights a good neonatal care practice, once, since nCPAP was introduced 
by Keszler in the 70’s, it has shown promising results in BPD’s incidence and severity 
[26]. Invasive mechanical ventilation is a well-known risk factor for the development of 
BPD and all efforts must be done to implement non-invasive mechanical ventilation in 
this high risk preterm infants [3,27]. 
Another fact that reinforces the good practices in peri and neonatal care of our 
hospital is the statistically significant decrease of nosocomial sepsis, which had already 
been reported by another study [28]. The importance of this data relates not only to the 
association between nosocomial sepsis and unfavorable neonatal outcomes, as was 
observed in a recent multicenter study showing that sepsis is one of the most common 
cause of deaths in NICUs [29] and BPD development [3,27].  
With regard to BPD severity, our data show that there was a lower number of 
severe BPD diagnosed in the second decade of the study (table 1). Comparing the two 
decades, in spite of no significant difference was observed, the prevalence of severe BPD 
decreased and the cases of mild/moderate BPD increased. Probably in the first ten years 
of this study, severe BPD was related to the greater use of IMV, since there was an 
association between these two entities [3]. Although there were no significant difference 
in gestational age and birth weight between the two epochs of our study, in the second 
epoch there were admitted more severe patients, proven by worse Apgar scores as 
mentioned previously. Clinical practices in neonatal intensive care units differ from one 
to another and benchmarking among them it´s crucial to improve outcomes [30].  
With respect to clinical status at the discharge there were no significant differences 
between the two epochs. Taking into account that in the second decade more severe 
infants were admitted, this seems to be an encouraging information. 
In conclusion, the improvement on perinatal and neonatal intensive care practices 
implemented on the last years, contributed to the better evolution of our preterm infants. 
Moreover, even in the absence of an effective therapy for BPD, professionals should be 
sensitized to prevent known BPD risk factors and to improve the management of these 
preterm infants. 
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Table 1. Number of preterm infants with ≤1500g of birth weight or ≤32 weeks gestational 
age admitted in our Neonatal Intensive Care Unit in the study period. 
 Total 1996-
2005 
2006-
2015 
P value 
NICU admissions, n (%) 1196 
(100) 
640 
(53.5) 
556 
(46.5) 
0.047* 
Deceased preterm infants, n (%) 229 
(19.1) 
149 
(23.3) 
80 
(14.4) 
<0.001* 
Deceased and preterm infants with 
bronchopulmonary dysplasia , n (%) 
325 
(27.2) 
211 
(33.0) 
114 
(20.5) 
<0.001* 
Survivors with bronchopulmonary 
dysplasia, n (%) 
96 (8.0) 62 (9.7) 34 (6.1) 0.023* 
Abbreviation: NICU – neonatal intensive care unit 
*Chi-square test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Maternal, prenatal, and perinatal data of infants with bronchopulmonary 
dysplasia. 
 Total 
n=96 
1996-2005 
n=62 
2006-2015 
n=34 
P value 
Gender, n (%)     
       Male 66 (68.8) 43 (69.4) 23 (67.6) 0.863* 
       Female 30 (31.3) 19 (30.6) 11 (32.4)  
Gestational age, mean (±SD) 
(weeks) 
27.63 
(0.220) 
27.74 
(0.250) 
27.41 
(0.425) 
0.475§ 
Birth weight, mean (±SD) 
(grams) 
962.53 
(33.891) 
995.42 
(40.065) 
902.56 
(61.292) 
0.192§ 
Small for gestational age, n 
(%) 
22 (22.9) 10 (16.1) 12 (35.3) 0.033* 
Less than 1000g, n (%) 63 (65.6) 38 (61.3) 25 (73.5) 0.227* 
Maternal age, median (min-
max) (years) 
31.00 (16-
42) 
30.50 (16-
42) 
31.00 (20-
39) 
0.979¥ 
Preeclampsia, n (%) 21 (21.9) 9 (14.5) 12 (35.3) 0.019* 
Change in umbilical flows, n 
(%) 
17 (17.7) 6 (9.7) 11 (32.4) 0.005* 
Change in cerebral flows, n 
(%) 
16 (16.7) 6 (9.7) 10 (29.4) 0.013* 
Antenatal steroids, n (%) 87 (90.6) 55 (88.7) 32 (94.1) 0.485** 
       Full cycle 56 (65.9) 29 (54.7) 27 (84.4) 0.005* 
Histological 
chorioamnionitis, n (%) 
24 (25.8) 14 (23.7) 10 (29.4) 0.546* 
Delivery mode, n (%)     
       Vaginal 32 (33.3) 25 (40.3) 7 (20.6) 0.050* 
       C-section 64 (66.7) 37 (59.7) 27 (79.4)  
Apgar score, n (%)  
       1st minute <7 73 (76.0) 48 (77.4) 25 (73.5) 0.669* 
       5th minute <7 26 (22.7) 12 (20.0) 14 (41.2) 0.027* 
Respiratory management in 
the delivery room, n (%) 
    
       Spontaneous ventilation 3 (3.1) 2 (3.2) 1 (2.9) 0.999** 
       Endotracheal intubation 84 (87.5) 60 (96.8) 24 (70.6) <0.001** 
       Early nCPAP 15 (15.6) 1 (1.6) 14 (41.2) <0.001** 
Abbreviation: nCPAP – nasal continuous positive airway pressure 
*Chi-square test; **Fisher’s exact test; ¥ Mann-Whitney U test, §Independent t test 
 
 
 
 
 
 
 
 
 
Table 3. Neonatal Period: morbimortality and management of infants with 
bronchopulmonary dysplasia. 
 Total 
n=96 
1996-2005 
n=62 
2006-2015 
n=34 
P value 
Respiratory distress syndrome, n (%) 88 (91.7) 55 (88.7) 33 (97.1) 0.253** 
Surfactant administration, n (%) 81 (84.4) 51 (82.3) 30 (88.2) 0.563** 
Surfactant, median (min-max) 
(doses) 
2.00 (1-5) 2.00 (1-3) 2.00 (1-5) 0.361¥ 
Invasive mechanical ventilation, n 
(%) 
90 (93.8) 60 (96.8) 30 (88.2) 0.181** 
Invasive mechanical ventilation, 
median (min-max) (days)  
30.50 (1-
211) 
39.50 (1-
211) 
20.00 (2-
138) 
0.013¥ 
nCPAP, n (%) 82 (85.4) 50 (80.6) 32 (94.1) 0.128** 
nCPAP, median (min-max) (days) 32.00 (1-
161) 
22.50 (1-
161) 
45.50 (7-
76) 
<0.001¥ 
Oxygen, n (%) 96 (100) 62 (100) 34 (100) - 
Oxygen, median (min-max) (days) 70.00 (22-
260) 
69.00 (28-
260) 
71.50 (22-
191) 
0.412¥ 
Bronchopulmonary dysplasia, n (%)     
       Mild/Moderate 70 (72.9) 43 (69.4) 27 (79.4) 0.458* 
       Severe 26 (27.1) 19 (30.6) 7 (20.6)  
Patent ductus arteriosus, n (%) 65 (67.7) 43 (69.4) 22 (64.7) 0.641* 
       With medical treatment 59 (95.2) 37 (94.9) 22 (95.7) 0.999** 
       With surgical treatment 10 (16.1) 4 (10.3) 6 (26.1) 0.153** 
Nosocomial sepsis, n (%) 74 (77.1) 52 (83.9) 22 (64.7) 0.033* 
Necrotizing enterocolitis ≥2A, n (%) 3 (3.1) 3 (4.8) 0 (0) 0.550** 
Retinopathy of prematurity ≥2, n (%) 29 (30.2) 14 (22.6) 15 (44.1) 0.028* 
Intraventricular hemorrhage ≥III, n 
(%) 
21 (21.9) 8 (12.9) 13 (38.2) 0.004* 
Cystic periventricular leukomalacia, 
n (%) 
7 (7.3) 4 (6.5) 3 (8.8) 0.695** 
Parenteral nutrition, n (%) 95 (99.0) 61 (98.4) 34 (100) 0.999** 
Parenteral nutrition, median (min-
max) (days) 
36.00 (8-
145) 
40.00 (8-
145) 
33.0 (12-
101) 
0.070¥ 
NICU stay, median (min-max) (days) 78.50 (21-
259) 
74.00 (29-
259) 
86.00 (21-
191) 
0.191¥ 
Sequels, n (%)     
            O2 requirement 25 (30.1) 14 (26.4) 11 (36.7) 0.328* 
            Tracheostomy 2 (2.4) 1 (1.9) 1 (3.3) 0.999** 
            No feed autonomy 1 (1.2) 1 (1.9) 0 (0) 0.999** 
            Jejune/iliostomy 1 (1.2) 1 (1.9) 0 (0) 0.999** 
            Ventriculoperitoneal shunt 2 (2.4) 0 (0) 2 (6.7) 0.128** 
Deceased, n (%) 13 (13.5) 9 (14.5) 4 (11.8) 0.999** 
Abbreviations: nCPAP – nasal continuous positive airway pressure; NICU – neonatal intensive care unit 
*Chi-square test; **Fisher’s exact test; ¥ Mann-Whitney U test 
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